Receptos files for $86.3m IPO
This article was originally published in Scrip
Executive Summary
Receptos intends to raise $86.3 million in an initial public offering to fund mid-stage clinical trials for its once-daily, oral multiple sclerosis drug RPC1063 and the antibody RPC4046 for the treatment of eosinophilic esophagitis (EoE).